Month: April 2023

Zevra seeks to expand KP1077 clinical program to address multiple rare sleep disorders CELEBRATION, Fla., April 04, 2023 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced the submission of an Investigational New Drug (IND) application seeking authorization from the U.S. Food and Drug Administration (“FDA”) to begin a Phase 1 clinical trial of KP1077 in narcolepsy. Once the clinical investigation plan proposed in the IND has been cleared to proceed by the FDA, Zevra plans to initiate its first of several Phase 1 clinical trials of KP1077 as early as the second quarter of 2023. KP1077 is also currently being evaluated in a Phase 2 clinical trial for the treatment of idiopathic hypersomnia (“IH”). Those data have...

MONTREAL, April 04, 2023 (GLOBE NEWSWIRE) — Vision Marine Technologies Inc. (NASDAQ: VMAR) (“Vision Marine” or the “Company”), a global leader and innovator within the performance electric recreational boating industry, is pleased to announce the appointment of Carter Murray as Chairman of the Company’s board of directors. Murray, a proven global executive, will work directly with Vision Marine’s Chief Executive Officer, Alex Mongeon, to continue transforming recreational boating through innovation, technology and superior performance with the Company’s leading powertrain technology and outboard electric engines. “The addition of Mr. Murray to the Board is a testament to our commitment to delivering the highest quality products and services to our customers,” said Mongeon. “The appointment of Carter is a game-changer for Vision...

Approximately two-thirds of trial patients with Major Depressive Disorder achieving remission following SPL026 treatment sustained remission to six-monthsAggregated Remission Rates Aggregated Remission RatesLONDON, April 04, 2023 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces positive six-month data from the Company’s Phase IIa clinical trial of SPL026. In the study, patients with Major Depressive Disorder (“MDD”) received SPL026, the Company’s proprietary, pharmaceutical-grade formulation of N,N-Dimethyltryptamine (“DMT”), during a clinical session with supportive therapy. New data from the Phase IIa trial shows that among the patients who had...

Opportunity to Accelerate Long-Term Organic Growth and Expand Patient Access CINCINNATI, April 04, 2023 (GLOBE NEWSWIRE) — Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, is very pleased to announce the execution of a national insurance contract with a top five health insurer based on membership in the United States1. This represents the second national insurance contract the Company has signed since April 2022. Management Commentary “Our strong start to the year has continued with the execution of our second national insurance contract with another top five health insurer in the United States. At present, we are providing cost-effective patient care to over 270,000 active patients across the nation and I am very...

Mosaic Minerals Pluton SM Property Map Mosaic Minerals Pluton SM Property MapMosaic Minerals Lithium Properties Map Mosaic Minerals Lithium Properties MapMONTREAL, April 04, 2023 (GLOBE NEWSWIRE) — Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “The Company”) would first like to congratulate the management of Patriot Battery Metals for the success it is achieving in the development of its Corvette project, in James Bay. Recent drilling results continue to demonstrate the importance of this project, which could eventually lead to a major lithium deposit. Mosaic, through its Pluton SM project located on the eastern edge of the Corvette project, is very pleased to be able to actively participate in the development of this strategic territory with a first phase of work including exploration and ground sampling. The potential...

TORONTO, ON, April 04, 2023 (GLOBE NEWSWIRE) — Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) announces that it has been granted a management cease trade order (“MCTO”) by the Ontario Securities Commission (the “OSC”), as its principal regulator, under National Policy 12-203 – Cease Trade Orders for Continuous Disclosure Defaults (“NP 12-203”). On March 22, 2023, the Company announced that (i) it would not be filing its annual financial statements, the related management’s discussion and analysis and annual information form, and the accompanying chief executive officer and chief financial officer certification for its financial year ended December 31, 2022 (collectively, the “Annual Filing Documents”) within the time period prescribed by National Instrument 51-102 – Continuous Disclosure Obligations and National...

MELBOURNE, Australia and SAN FRANCISCO, April 04, 2023 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first participant has been dosed in the United Kingdom in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA). “MSA is a rare and highly debilitating Parkinsonian disorder, and our Phase 2 clinical program is designed to evaluate the effects of ATH434 in individuals with early-stage disease with no current therapeutic treatment options,” said David Stamler, M.D., Chief Executive Officer, Alterity. “With sites open in five countries, the clinical trial is steadily enrolling globally, and the enrollment of our first patient in...